ONMD (OneMedNet) ROCE %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ONMD OneMedNet Corp ONMD
8 GF Score
Price $0.65
GF Value $0.57
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is OneMedNet ROCE %?

OneMedNet ONMD -3.76% 8 ROCE % is 0.00% as of Mar. 2026. GuruFocus rates ONMD with a GF Score™ of 8/100 and a GF Value™ of $0.57 (Modestly Overvalued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OneMedNet's annualized ROCE % for the quarter that ended in Mar. 2026 was 0.00%.

OneMedNet  (NAS:ONMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OneMedNet ROCE % Related Terms

OneMedNet ROCE % Historical Data

* Premium members only.

The historical data trend for OneMedNet's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OneMedNet ROCE % Chart

OneMedNet Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

OneMedNet Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ONMD
8GF Score
OneMedNet Corp ONMD
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OneMedNet ROCE % Calculation

OneMedNet's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-2.733/( ( (3.727 - 19.228) + (2.151 - 4.825) )/ 2 )
=-2.733/( (-15.501+-2.674)/ 2 )
=-2.733/-9.0875
=30.07 %

OneMedNet's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-9.772/( ( (2.151 - 4.825) + (1.507 - 5.355) )/ 2 )
=-9.772/( ( -2.674 + -3.848 )/ 2 )
=-9.772/-3.261
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
OneMedNet (ONMD) has a ROCE % of 0.00% as of Mar. 2026.
Is OneMedNet's ROCE % too high?
OneMedNet's current ROCE % is 0.00%. Overall, OneMedNet has a GF Score™ of 8/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OneMedNet's ROCE % compare to CRVW and BEAT?
OneMedNet's ROCE % of 0.00% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.36, based on 643 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OneMedNet's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OneMedNet stock overvalued right now?
Based on GuruFocus' analysis, OneMedNet (ONMD) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.57, compared to a current price of $0.65 — trading 13.9% above its estimated fair value. The current ROCE % is 0.00%. OneMedNet's overall GF Score™ is 8/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For OneMedNet (ONMD), the current ROCE % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OneMedNet (ONMD) Overvalued in 2026?

Based on GuruFocus' analysis, OneMedNet stock appears to be overvalued. The current stock price of $0.65 is trading 13.9% above its estimated GF Value™ of $0.57. GuruFocus considers OneMedNet to be Modestly Overvalued.

Key valuation signals for ONMD:

  • ROCE %: 0.00%
  • GF Value™: $0.57 vs. price of $0.65 (13.9% above fair value)
  • GF Score™: 8/100 with 8 warning signs

No single metric tells the full story. See the ONMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OneMedNet Business Description

Address 6385 Old Shady Oak Road, Suite 250, Eden Prairie, MN, USA, 55344
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.
8GF Score

Get the complete analysis for ONMD

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price
$0.57
GF Value